# Southern Element

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/southern-element

- Industry: Medical Devices & Equipment
- Headquarters: Nanjing, China
- Website: www.nfybio.com
- Latest round: Series A (Jul 16, 2025)
- Investors on record: 2

## About

Established in 2021 and based in Nanjing, China, Southern Element operates as a hemostatic polysaccharide product developer that provides hemostatic materials and long-lasting medical aesthetic fillers. The company established key laboratory of metabolic engineering and biosynthesis technology, ministry of industry and information iechnology with Nanjing University of Science and Technology.

The company provides hemostatic materials and long-lasting medical aesthetic fillers for many fields, such as medicine, biotechnology, medical aesthetics, emergency rescue and battlefield rescue. Its products include medical and aesthetic products, bacterial growth assay, molecular reagent kit and innovative hemostatic materials - Hemoadhican. Medical and aesthetic products include cross-linked silk sugar - Lubcan. Molecular reagent kit includes KARROTEN blood genomic DNA extraction kit, Karrol RNA reagent and Karrol RNA mate.

## Funding rounds

- Series A, Jul 16, 2025 — Lotus Lake Capital, Fosun Health Capital

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series A